NVS
NOVARTIS AG
NYSE: NVS · Basel, V8 · Healthcare
$149.12+2.70 (+1.84%)Closed
Market Cap$284.52B
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$110.15 – $163.64
Avg Volume1.7M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$149.12+51.2%
Pipeline

Drug candidates sponsored by NOVARTIS · ClinicalTrials.gov

82 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Unnamed
Prevention of Meningococcal Infection
Completed
2005-12past
1
Phase 4Enteric coated mycophenolate sodium (Myfortic®)
Kidney Transplantation
Terminated
2008-05past
1
Phase 4Letrozole
Metastatic Breast Cancer
Terminated
2008-10past
1
Phase 4valsartan and amlodipine
Hypertension
Completed
2009-01past
1
Phase 4Zoledronic acid
Prostate Cancer+1 more
Completed
2009-11past
5
Phase 4Rivastigmine 4.6 mg/24 h (5 cm^2)
Alzheimer's Disease
Completed
2012-01past
1
Phase 4QVA149
Chronic Obstructive Pulmonary Disease+1 more
Completed
2015-01past
1
Phase 4omalizumab
Asthma+1 more
Completed
2015-08-06past
2
Phase 4Aliskiren
Hypertension+2 more
Completed
2018-06past
4
Phase 4LCZ696 (sacubitril/valsartan)
Heart Failure
Completed
2018-10-22past
1
Phase 4everolimus
Pancreatic Neuroendocrine Tumors
Completed
2024-02-22past
1
Phase 4inclisiran
Primary Hypercholesterolemia+5 more
Completed
2026-01-13past
2
Phase 3Vildagliptin
Diabetes Mellitus, Type 2
Completed
2006-02past
1
Phase 3Diclofenac Topical Sodium Gel 1%
Osteoarthritis
Completed
2006-06past
1
Phase 3Vildagliptin AM
Diabetes Mellitus, Type 2
Completed
2007-11past
1
Phase 3Amlodipine
Hypertension
Completed
2007-12past
1
Phase 3ranibizumab 0.5 mg
Age Related Macular Degeneration
Completed
2010-07past
1
Phase 3Agomelatine (AGO178C)
Major Depressive Disorder
Completed
2011-06past
1
Phase 3Meningococcal ACWY conjugate vaccine
Bacterial Meningitis
Completed
2012-01past
1
Phase 3Terbinafine
Tinea Pedis
Completed
2012-02past
1
Phase 3Rabies
Rabies+1 more
Completed
2012-12past
1
Phase 3Ruxolitinib
Myelofibrosis
Completed
2015-03-04past
1
Phase 3standard therapy
Lung Transplantation
Completed
2017-01-05past
1
Phase 3AIN457
Spondyloarthritis+1 more
Completed
2019-02-15past
2
Phase 3Onasemnogene Abeparvovec-xioi
SMA - Spinal Muscular Atrophy+1 more
Completed
2019-11-12past
1
Phase 3LCZ696
Heart Failure With Preserved Ejection Fraction (HFpEF)
Terminated
2019-11-19past
1
Phase 3EFG816
Carcinoma, Non-small Cell Lung
Withdrawn
2020-08-13past
1
Phase 3brolucizumab
Age-related Macular Degeneration (AMD)
Withdrawn
2021-06-21past
1
Phase 3Brolucizumab 6 mg
Branch Retinal Vein Occlusion
Terminated
2021-07-26past
1
Phase 3Canakinumab
Non-Small Cell Lung Cancer+1 more
Terminated
2022-03-17past
2
Phase 3Ofatumumab
Multiple Sclerosis+1 more
Completed
2025-11-04past
2
Phase 3Tisagenlecleucel
Follicular Lymphoma (FL)
Active, not recruiting
2028-07-25
1
Phase 3Octreotide LAR
Somatostatin Receptor Positive (SSTR+)+1 more
Recruiting
2028-12-08
1
Phase 3Xylometazoline
Common Cold
Completed—1
Phase 2indacaterol/glycopyrrolate
Chronic Obstructive Pulmonary Disease (COPD)
Completed
2008-09past
1
Phase 1Nilotinib
Chronic Myelogenous Leukemia+1 more
Completed
2009-12past
1
Phase 2H5N1 pandemic Influenza vaccine 3.75µg
Pandemic H5N1 Influenza
Completed
2009-12past
1
Phase 2Panobinostat
Prostate Cancer
Completed
2010-11-05past
1
Phase 2Imatinib Mesylate
Gastrointestinal Stromal Tumors+4 more
Completed
2012-01past
2
Phase 2Group B Streptococcus Trivalent Vaccine
Streptococcal Infection+2 more
Completed
2013-04past
1
Phase 2Deferasirox and Deferoxamine
Cardiac Iron Overload
Completed
2013-11past
1
Phase 2MenABCWY+OMV
Meningococcal Disease
Completed
2014-05past
1
Phase 2FTY720
Asthma+1 more
Completed
2014-10past
2
Phase 2Terlipressin acetate
Compensated Cirrhosis and Portal Hypertension
Completed
2014-12past
1
Phase 2BKM120
HER2-positive Newly Diagnosed, Primary Breast Cancer
Completed
2015-02-18past
1
Phase 2LFG316
Geographic Atrophy+4 more
Completed
2017-02-16past
2
Phase 1QBW276
Pulmonary Cystic Fibrosis
Completed
2018-04-24past
1
Phase 2Deferasirox granule formulation
Transfusion-dependent Anemia
Completed
2018-05-31past
1
Phase 2LAG525
Triple-negative Breast Cancer
Completed
2020-02-27past
1
Phase 2Tropifexor (LJN452)
Non-alcoholic Steatohepatitis (NASH)
Terminated
2020-04-06past
1
Phase 1Trametinib
Cancer
Completed
2020-12-29past
1
Phase 2CFZ533
Lupus Nephritis
Completed
2023-06-29past
1
Phase 2Placebo
Alzheimer Disease+2 more
Completed
2024-11-01past
3
Phase 2KAE609
Uncomplicated Plasmodium Falciparum Malaria
Completed
2025-03-05past
1
Phase 2Glycopyrronium bromide 25ug
Asthma
Recruiting
2027-07-30
1
Phase 2influenza vaccine
Influenza
Completed—1
Phase 2Surface Antigen, Inactivated, Influenza (form.2006-07)
Influenza
Completed—1
Phase 1QAK423A
Chronic Obstructive Pulmonary Disease
Completed
2005-02past
1
Phase 1AEB071
Healthy
Completed
2006-07past
1
Phase 1imatinib
Healthy
Completed
2006-11past
1
Phase 1Haemophilus influenzae type b
Haemophilus Influenzae Type b
Completed
2008-10past
1
Phase 1TAP311 capsules
Dyslipidaemia
Completed
2012-12past
1
Phase 1SOM230
Renal Impairment
Completed
2014-05past
1
Phase 1LDE225
Dose Escalation+11 more
Completed
2015-04past
1
Phase 1GSK2118436
Cancer
Completed
2018-04-09past
1
Phase 1ribociclib
Solid Tumors for Phase Ib+3 more
Terminated
2019-09-24past
2
Phase 1PDR001
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Completed
2021-03-17past
1
Phase 1225Ac-ETN029
Small Cell Lung Carcinoma+3 more
Recruiting
2031-08-29
1
Phase 1Secukinumab
Juvenile Psoriatic Arthritis
Recruiting
2032-11-30
1
Phase 1Tobramycin
Cystic Fibrosis
Completed—1
N/AUnnamed
Pandemic Influenza A (H1N1)+1 more
Completed
2011-03past
1
N/AUnnamed
Age-related Macular Degeneration (AMD)
Completed
2020-11-20past
1
N/AUnnamed
Chronic Iron Overload
Completed
2021-10-29past
1
N/AUnnamed
Secondary Progressive Multiple Sclerosis
Completed
2022-04-20past
1
N/AUnnamed
Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation
Completed
2022-11-02past
1
N/AUnnamed
Diffuse Large B-cell Lymphoma+1 more
Completed
2023-04-28past
1
N/AUnnamed
Hypertension
Completed
2023-11-08past
1
N/AUnnamed
Somatostatin Receptor-positive GEP-NET
Completed
2024-07-08past
1
N/AUnnamed
Dyslipidemia, Hypercholesterolemia
Not yet recruiting
2026-07-30
1
N/AUnnamed
Hidradenitis Suppurativa
Active, not recruiting
2026-12-31
1
N/AUnnamed
Pediatric Chronic Heart Failure
Recruiting
2027-11-30
1
N/AUnnamed
Psoriasis
Completed—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for NVS. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.